NUR 521 AVD PHARM BLUEPRINT EXAM 1
BLUEPRINT ANSWERS MINUS THE PROTOTYPE DRUG LIST QUESTIONS WITH COMPLETE
SOLUTIONS 2026/2027
Aligned with NUR 521 Advanced Pharmacology Course Syllabus, AACN Essentials of Master's Education, and Advanced
Pharmacology Competencies (2026/2027 Edition)
Total Questions: 100 Cognitive Distribution: 25% Recall / 50% Application / 25% Analysis
Format: Question Style:
Multiple Choice (4 options, single best answer) 75% Scenario-based / 25% Direct Knowledge
Sections: 9 (Pharmacology Body Systems) Special Inclusions: 15 scenarios, 10 pharmacogenomics, 10 drug interaction
Instructions to the Candidate: Read each question carefully and select the single best answer. Each question has only
one correct response. Mark your answer by identifying the option labeled *[CORRECT]*. After each question, a detailed
rationale explains why the correct answer is best and why the other options are incorrect, grounded in advanced
pharmacology principles, current FDA labeling, and evidence-based clinical guidelines (AHA/ACC, ADA, GOLD, GINA,
IDSA, CPIC, UpToDate). Pharmacogenomic considerations and drug interactions are emphasized throughout to align with
the AACN Essentials of Master's Education in Nursing and advanced pharmacology competencies.
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient receives an oral dose of 100 mg of a drug with an oral bioavailability of 0.40. What is the
actual amount of drug reaching the systemic circulation, and which pharmacokinetic concept primarily explains the
loss of the remaining dose?
A. 40 mg reaches systemic circulation; loss is due to renal excretion of unchanged drug
B. 40 mg reaches systemic circulation; loss is primarily due to first-pass hepatic metabolism
*[CORRECT]*
C. 100 mg reaches systemic circulation; bioavailability only affects onset, not extent
D. 60 mg reaches systemic circulation; loss is due to gastric acid degradation only
Correct Answer: B
Rationale: Bioavailability (F) = fraction of administered dose reaching systemic circulation unchanged. 100 mg × 0.40 =
40 mg reaches systemic circulation. For oral medications, the primary cause of reduced bioavailability is first-pass
metabolism by hepatic enzymes (CYP450) and gut wall metabolism before the drug enters the systemic circulation. Renal
excretion occurs after systemic absorption, and gastric degradation only affects acid-labile drugs.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 1
, Q2: A patient on long-term phenytoin therapy is newly started on carbamazepine. Two weeks later, the patient's
seizures are no longer controlled. The nurse recognizes that this interaction is best explained by which mechanism?
A. Carbamazepine inhibits CYP3A4, increasing phenytoin clearance
B. Carbamazepine induces CYP450 enzymes, increasing phenytoin metabolism *[CORRECT]*
C. Carbamazepine competes for renal tubular secretion, reducing phenytoin excretion
D. Carbamazepine displaces phenytoin from plasma proteins, increasing free drug transiently
Correct Answer: B
Rationale: Carbamazepine is a potent inducer of hepatic CYP450 enzymes (particularly CYP3A4 and CYP2C9). Enzyme
induction increases the synthesis of metabolic enzymes, accelerating the metabolism of concurrently administered drugs
like phenytoin, leading to subtherapeutic levels and breakthrough seizures. Induction takes 1-2 weeks to manifest,
matching this clinical timeline. CYP inhibition (option A) would cause phenytoin toxicity, not loss of seizure control.
Q3: A drug has a volume of distribution (Vd) of 5 L in a 70 kg adult. Based on this Vd, which statement best
describes the drug's distribution pattern?
A. The drug is extensively distributed into total body water (42 L)
B. The drug is confined primarily to the plasma compartment *[CORRECT]*
C. The drug is highly lipophilic and sequestered in adipose tissue
D. The drug distributes freely across the blood-brain barrier
Correct Answer: B
Rationale: A Vd of approximately 5 L corresponds to plasma volume, indicating the drug remains largely within the
vascular compartment. This pattern is typical of large or highly protein-bound molecules (e.g., warfarin, heparin). A Vd of
42 L suggests distribution into total body water; values exceeding body weight suggest tissue sequestration (e.g., lipophilic
drugs like amiodarone with Vd ~60 L/kg). Vd alone does not predict blood-brain barrier permeability.
Q4: A patient taking warfarin (highly protein-bound, 99%) is newly prescribed sulfamethoxazole/trimethoprim.
Three days later, the INR is 4.8 (target 2.0-3.0). Which pharmacokinetic mechanism best explains this interaction?
A. Sulfamethoxazole induces warfarin metabolism via CYP2C9
B. Sulfamethoxazole displaces warfarin from albumin, transiently increasing free warfarin
*[CORRECT]*
C. Sulfamethoxazole enhances renal elimination of warfarin metabolites
D. Sulfamethoxazole increases gastrointestinal absorption of warfarin
Correct Answer: B
Rationale: Warfarin is 99% protein-bound to albumin. Sulfonamides also bind albumin and displace warfarin, transiently
increasing the free (active) fraction. The displaced warfarin redistributes into tissues and is metabolized, but the acute rise
in free fraction amplifies anticoagulation. Additionally, sulfamethoxazole inhibits CYP2C9 (further impairing warfarin
clearance), making this a dual mechanism interaction. The displacement alone explains the rapid INR rise within days.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 2
, Q5: A patient asks why grapefruit juice should be avoided while taking simvastatin. The advanced practice nurse
correctly explains that grapefruit juice:
A. Induces CYP3A4 in the liver, accelerating statin clearance
B. Irreversibly inhibits intestinal CYP3A4, increasing systemic statin exposure *[CORRECT]*
C. Binds statins in the gut lumen, preventing absorption
D. Displaces statins from plasma proteins, increasing free drug
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins that irreversibly (mechanism-based) inhibit intestinal CYP3A4.
Because this inhibition occurs at the intestinal wall, the effect is most pronounced for drugs with high first-pass
metabolism by gut CYP3A4 (e.g., simvastatin, lovastatin, cyclosporine). The resulting increase in bioavailability can raise
simvastatin AUC up to 5-fold, significantly increasing risk of myopathy and rhabdomyolysis. Hepatic CYP3A4 is less
affected because furanocoumarins do not reach therapeutic concentrations in portal blood.
Q6: A drug has a half-life of 12 hours. Without a loading dose, approximately how long will it take to reach
approximately 94% of steady-state concentration?
A. 12 hours (one half-life)
B. 24 hours (two half-lives)
C. 36 hours (three half-lives)
D. 60 hours (approximately four half-lives) *[CORRECT]*
Correct Answer: D
Rationale: Steady state is achieved after approximately 4-5 half-lives of consistent dosing. At 4 half-lives, ~94% of steady
state is reached; at 5 half-lives, ~97%. With a t1/2 of 12 hours, 4 half-lives = 48 hours (roughly '60 hours' captures 5
half-lives for near-complete steady state). This principle underlies the use of loading doses for drugs with long half-lives
(e.g., amiodarone, digoxin) when rapid therapeutic effect is needed.
Q7: A 60 kg patient requires a therapeutic serum concentration of 10 mg/L for a drug with a volume of distribution
of 0.5 L/kg. Calculate the loading dose assuming 100% bioavailability.
A. 100 mg
B. 300 mg *[CORRECT]*
C. 500 mg
D. 1000 mg
Correct Answer: B
Rationale: Loading dose (LD) = (target concentration × Vd) / bioavailability. Vd = 0.5 L/kg × 60 kg = 30 L. LD = 10
mg/L × 30 L = 300 mg. Loading doses rapidly achieve therapeutic concentrations without waiting for steady state (4-5
half-lives), which is critical for drugs like antiarrhythmics, antibiotics in severe infections, and antiepileptics in status
epilepticus.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 3
, Q8: Which of the following drugs has the narrowest therapeutic index and therefore requires routine therapeutic drug
monitoring (TDM)?
A. Metformin
B. Lisinopril
C. Vancomycin *[CORRECT]*
D. Acetaminophen
Correct Answer: C
Rationale: Vancomycin has a narrow therapeutic index; trough levels must be monitored to ensure efficacy (trough 15-20
mg/L for serious MRSA infections) while avoiding nephrotoxicity and ototoxicity. Digoxin, lithium, aminoglycosides,
warfarin (via INR), and certain antiepileptics also require TDM. Metformin, lisinopril, and acetaminophen have wide
therapeutic indices and do not require routine serum monitoring.
Q9: When monitoring vancomycin therapy, the trough level is drawn just before the next dose, while the peak is
drawn 1-2 hours post-infusion. Why is the trough level generally considered more clinically useful than the peak for
vancomycin?
A. Trough levels predict efficacy; peak levels predict nephrotoxicity only
B. Trough levels predict both efficacy and accumulation-related nephrotoxicity *[CORRECT]*
C. Peak levels are unreliable due to rapid tissue distribution
D. Vancomycin has no toxic concentration; only efficacy matters
Correct Answer: B
Rationale: Vancomycin trough concentrations (target 15-20 mg/L for serious infections) are used to assess both efficacy
(above MIC of the pathogen) and accumulation that signals risk of nephrotoxicity. Because vancomycin is
concentration-independent (time-dependent) in its bacterial killing, trough monitoring is sufficient for most patients.
AUC-based monitoring is increasingly replacing trough-only strategies, but trough remains the standard practical
approach per current NUR 521 advanced pharmacology guidance.
Q10: An 82-year-old patient with CKD stage 4 (eGFR 22 mL/min/1.73m²) is prescribed a renally cleared antibiotic.
Which pharmacokinetic parameter is most directly affected, and what is the appropriate clinical response?
A. Absorption is impaired; switch to intravenous route
B. Volume of distribution is increased; increase loading dose
C. Clearance is reduced; extend dosing interval or reduce dose *[CORRECT]*
D. First-pass metabolism increases; increase oral dose
Correct Answer: C
Rationale: In renal impairment, drug clearance (CL) is reduced, prolonging half-life and increasing risk of accumulation.
The standard approach is to extend the dosing interval (e.g., every 8 hours → every 24 hours) or reduce individual doses
while maintaining the same interval. Loading doses are typically unchanged because Vd is not significantly altered by
renal failure. The Cockcroft-Gault or CKD-EPI equation guides dose adjustment; for drugs like gabapentin, vancomycin,
and digoxin, dose adjustment is mandatory.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 4
BLUEPRINT ANSWERS MINUS THE PROTOTYPE DRUG LIST QUESTIONS WITH COMPLETE
SOLUTIONS 2026/2027
Aligned with NUR 521 Advanced Pharmacology Course Syllabus, AACN Essentials of Master's Education, and Advanced
Pharmacology Competencies (2026/2027 Edition)
Total Questions: 100 Cognitive Distribution: 25% Recall / 50% Application / 25% Analysis
Format: Question Style:
Multiple Choice (4 options, single best answer) 75% Scenario-based / 25% Direct Knowledge
Sections: 9 (Pharmacology Body Systems) Special Inclusions: 15 scenarios, 10 pharmacogenomics, 10 drug interaction
Instructions to the Candidate: Read each question carefully and select the single best answer. Each question has only
one correct response. Mark your answer by identifying the option labeled *[CORRECT]*. After each question, a detailed
rationale explains why the correct answer is best and why the other options are incorrect, grounded in advanced
pharmacology principles, current FDA labeling, and evidence-based clinical guidelines (AHA/ACC, ADA, GOLD, GINA,
IDSA, CPIC, UpToDate). Pharmacogenomic considerations and drug interactions are emphasized throughout to align with
the AACN Essentials of Master's Education in Nursing and advanced pharmacology competencies.
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient receives an oral dose of 100 mg of a drug with an oral bioavailability of 0.40. What is the
actual amount of drug reaching the systemic circulation, and which pharmacokinetic concept primarily explains the
loss of the remaining dose?
A. 40 mg reaches systemic circulation; loss is due to renal excretion of unchanged drug
B. 40 mg reaches systemic circulation; loss is primarily due to first-pass hepatic metabolism
*[CORRECT]*
C. 100 mg reaches systemic circulation; bioavailability only affects onset, not extent
D. 60 mg reaches systemic circulation; loss is due to gastric acid degradation only
Correct Answer: B
Rationale: Bioavailability (F) = fraction of administered dose reaching systemic circulation unchanged. 100 mg × 0.40 =
40 mg reaches systemic circulation. For oral medications, the primary cause of reduced bioavailability is first-pass
metabolism by hepatic enzymes (CYP450) and gut wall metabolism before the drug enters the systemic circulation. Renal
excretion occurs after systemic absorption, and gastric degradation only affects acid-labile drugs.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 1
, Q2: A patient on long-term phenytoin therapy is newly started on carbamazepine. Two weeks later, the patient's
seizures are no longer controlled. The nurse recognizes that this interaction is best explained by which mechanism?
A. Carbamazepine inhibits CYP3A4, increasing phenytoin clearance
B. Carbamazepine induces CYP450 enzymes, increasing phenytoin metabolism *[CORRECT]*
C. Carbamazepine competes for renal tubular secretion, reducing phenytoin excretion
D. Carbamazepine displaces phenytoin from plasma proteins, increasing free drug transiently
Correct Answer: B
Rationale: Carbamazepine is a potent inducer of hepatic CYP450 enzymes (particularly CYP3A4 and CYP2C9). Enzyme
induction increases the synthesis of metabolic enzymes, accelerating the metabolism of concurrently administered drugs
like phenytoin, leading to subtherapeutic levels and breakthrough seizures. Induction takes 1-2 weeks to manifest,
matching this clinical timeline. CYP inhibition (option A) would cause phenytoin toxicity, not loss of seizure control.
Q3: A drug has a volume of distribution (Vd) of 5 L in a 70 kg adult. Based on this Vd, which statement best
describes the drug's distribution pattern?
A. The drug is extensively distributed into total body water (42 L)
B. The drug is confined primarily to the plasma compartment *[CORRECT]*
C. The drug is highly lipophilic and sequestered in adipose tissue
D. The drug distributes freely across the blood-brain barrier
Correct Answer: B
Rationale: A Vd of approximately 5 L corresponds to plasma volume, indicating the drug remains largely within the
vascular compartment. This pattern is typical of large or highly protein-bound molecules (e.g., warfarin, heparin). A Vd of
42 L suggests distribution into total body water; values exceeding body weight suggest tissue sequestration (e.g., lipophilic
drugs like amiodarone with Vd ~60 L/kg). Vd alone does not predict blood-brain barrier permeability.
Q4: A patient taking warfarin (highly protein-bound, 99%) is newly prescribed sulfamethoxazole/trimethoprim.
Three days later, the INR is 4.8 (target 2.0-3.0). Which pharmacokinetic mechanism best explains this interaction?
A. Sulfamethoxazole induces warfarin metabolism via CYP2C9
B. Sulfamethoxazole displaces warfarin from albumin, transiently increasing free warfarin
*[CORRECT]*
C. Sulfamethoxazole enhances renal elimination of warfarin metabolites
D. Sulfamethoxazole increases gastrointestinal absorption of warfarin
Correct Answer: B
Rationale: Warfarin is 99% protein-bound to albumin. Sulfonamides also bind albumin and displace warfarin, transiently
increasing the free (active) fraction. The displaced warfarin redistributes into tissues and is metabolized, but the acute rise
in free fraction amplifies anticoagulation. Additionally, sulfamethoxazole inhibits CYP2C9 (further impairing warfarin
clearance), making this a dual mechanism interaction. The displacement alone explains the rapid INR rise within days.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 2
, Q5: A patient asks why grapefruit juice should be avoided while taking simvastatin. The advanced practice nurse
correctly explains that grapefruit juice:
A. Induces CYP3A4 in the liver, accelerating statin clearance
B. Irreversibly inhibits intestinal CYP3A4, increasing systemic statin exposure *[CORRECT]*
C. Binds statins in the gut lumen, preventing absorption
D. Displaces statins from plasma proteins, increasing free drug
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins that irreversibly (mechanism-based) inhibit intestinal CYP3A4.
Because this inhibition occurs at the intestinal wall, the effect is most pronounced for drugs with high first-pass
metabolism by gut CYP3A4 (e.g., simvastatin, lovastatin, cyclosporine). The resulting increase in bioavailability can raise
simvastatin AUC up to 5-fold, significantly increasing risk of myopathy and rhabdomyolysis. Hepatic CYP3A4 is less
affected because furanocoumarins do not reach therapeutic concentrations in portal blood.
Q6: A drug has a half-life of 12 hours. Without a loading dose, approximately how long will it take to reach
approximately 94% of steady-state concentration?
A. 12 hours (one half-life)
B. 24 hours (two half-lives)
C. 36 hours (three half-lives)
D. 60 hours (approximately four half-lives) *[CORRECT]*
Correct Answer: D
Rationale: Steady state is achieved after approximately 4-5 half-lives of consistent dosing. At 4 half-lives, ~94% of steady
state is reached; at 5 half-lives, ~97%. With a t1/2 of 12 hours, 4 half-lives = 48 hours (roughly '60 hours' captures 5
half-lives for near-complete steady state). This principle underlies the use of loading doses for drugs with long half-lives
(e.g., amiodarone, digoxin) when rapid therapeutic effect is needed.
Q7: A 60 kg patient requires a therapeutic serum concentration of 10 mg/L for a drug with a volume of distribution
of 0.5 L/kg. Calculate the loading dose assuming 100% bioavailability.
A. 100 mg
B. 300 mg *[CORRECT]*
C. 500 mg
D. 1000 mg
Correct Answer: B
Rationale: Loading dose (LD) = (target concentration × Vd) / bioavailability. Vd = 0.5 L/kg × 60 kg = 30 L. LD = 10
mg/L × 30 L = 300 mg. Loading doses rapidly achieve therapeutic concentrations without waiting for steady state (4-5
half-lives), which is critical for drugs like antiarrhythmics, antibiotics in severe infections, and antiepileptics in status
epilepticus.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 3
, Q8: Which of the following drugs has the narrowest therapeutic index and therefore requires routine therapeutic drug
monitoring (TDM)?
A. Metformin
B. Lisinopril
C. Vancomycin *[CORRECT]*
D. Acetaminophen
Correct Answer: C
Rationale: Vancomycin has a narrow therapeutic index; trough levels must be monitored to ensure efficacy (trough 15-20
mg/L for serious MRSA infections) while avoiding nephrotoxicity and ototoxicity. Digoxin, lithium, aminoglycosides,
warfarin (via INR), and certain antiepileptics also require TDM. Metformin, lisinopril, and acetaminophen have wide
therapeutic indices and do not require routine serum monitoring.
Q9: When monitoring vancomycin therapy, the trough level is drawn just before the next dose, while the peak is
drawn 1-2 hours post-infusion. Why is the trough level generally considered more clinically useful than the peak for
vancomycin?
A. Trough levels predict efficacy; peak levels predict nephrotoxicity only
B. Trough levels predict both efficacy and accumulation-related nephrotoxicity *[CORRECT]*
C. Peak levels are unreliable due to rapid tissue distribution
D. Vancomycin has no toxic concentration; only efficacy matters
Correct Answer: B
Rationale: Vancomycin trough concentrations (target 15-20 mg/L for serious infections) are used to assess both efficacy
(above MIC of the pathogen) and accumulation that signals risk of nephrotoxicity. Because vancomycin is
concentration-independent (time-dependent) in its bacterial killing, trough monitoring is sufficient for most patients.
AUC-based monitoring is increasingly replacing trough-only strategies, but trough remains the standard practical
approach per current NUR 521 advanced pharmacology guidance.
Q10: An 82-year-old patient with CKD stage 4 (eGFR 22 mL/min/1.73m²) is prescribed a renally cleared antibiotic.
Which pharmacokinetic parameter is most directly affected, and what is the appropriate clinical response?
A. Absorption is impaired; switch to intravenous route
B. Volume of distribution is increased; increase loading dose
C. Clearance is reduced; extend dosing interval or reduce dose *[CORRECT]*
D. First-pass metabolism increases; increase oral dose
Correct Answer: C
Rationale: In renal impairment, drug clearance (CL) is reduced, prolonging half-life and increasing risk of accumulation.
The standard approach is to extend the dosing interval (e.g., every 8 hours → every 24 hours) or reduce individual doses
while maintaining the same interval. Loading doses are typically unchanged because Vd is not significantly altered by
renal failure. The Cockcroft-Gault or CKD-EPI equation guides dose adjustment; for drugs like gabapentin, vancomycin,
and digoxin, dose adjustment is mandatory.
NUR 521 Advanced Pharmacology — Blueprint Exam 1 (2026/2027) Page 4
